Improve Human Health to Preserve Patients’ Dignity

Leading the advancement of innovative therapies in genitourinary tumors and women's health

Highlights

Blue Light Cystoscopy System Approved for Marketing in China; “Blue Light Era” for Precision Treatment of Bladder Cancer Begins

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Core Areas

Urologic Oncology

Integrated diagnosis and treatment, reinforced by strengthened leadership

Women's Health

Building a robust and tiered gynecology pipeline with game-changing products

Breast and Gynecologic Oncology

Synergizing in-house R&D and licensing to cover both early- and late-stage needs

Global Partnership

News & Updates

Blue Light Cystoscopy System Approved for Marketing in China; “Blue Light Era” for Precision Treatment of Bladder Cancer Begins

Asieris Pharmaceuticals Releases 2025 Annual Report：Flagship Product Approval Marks Inflection Point; Commercialization 2.0 Drives Growth

Cevira® Endorsed with Level 1A Evidence in Expert Consensus, Establishing a New Benchmark for Non-Invasive Treatment of Cervical Precancerous Lesions

Asieris and SPH Kyuan Trade Announce Import and Distribution Strategic Partnership to Accelerate the Commercialization of Cevira®

Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

February 27, 2026

Asieris Announces European Medicines Agency Accepts Marketing Authorization Application for APL-1702

Technology Platform